期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅱ)——移植后白血病复发(2016年版) 被引量：32

The consensus of allogeneic hematopoietic transplantation for hematological diseases in China(2016)--post-transplant leukemia relapse
原文传递
导出
摘要 白血病复发是异基因造血干细胞移植(allo-HSCT)失败的主要原因之一。国际骨髓移植登记组(CIBMTR)的资料显示,复发在非血缘和同胞相合移植后的死因中分别占33%和47%。北京大学血液病研究所的资料显示,单倍型和同胞相合移植后的复发相关死亡率在总体人群中分别为15.6%和16.7%,在死因中分别占32%和42%。
作者 中华医学会血液学分会干细胞应用学组 黄晓军 王昱 许兰平 Chinese Society of Hematology,Chinese Medical Association;Huang XiaoJun(不详;Peking University People's Hospital,Peking University Institute of Hematology,Beijing 100044,China)
机构地区 不详 北京大学人民医院、北京大学血液病研究所
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第10期846-851,共6页 Chinese Journal of Hematology
关键词 异基因造血干细胞移植 白血病复发 移植后 血液系统疾病 移植治疗 专家 中国 骨髓移植
分类号 R733.7 [医药卫生—肿瘤] R55 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献42

  • 1http://www.cibmtr.org.
  • 2Yan CH, Xu LP, Wang FR, et al. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation [J]. Bone Marrow Transplant, 2016, 51 (3) :391- 397. doi: 10.1038/bmt.2015.306.
  • 3Bassan R, Spinelli O, Oldani E, et al. Improved risk classifica- tion for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) [J]. Blood, 2009, 113 (18):4153-4162. doi: 10.1182/blood-2008-11-185132.
  • 4Zhao XS, Yan CH, Liu DH, et al. Combined use of WT1 and flow eytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity [J]. Ann Hematol, 2013, 92 (8):1111-1119. doi: 10.1007/s00277- 013-1733-1.
  • 5Chen H, Liu KY, Xu LP, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome- positive acute lymphobla stic leukemia [J]. J Hematol Oncol, 2012, 5:29. doi: 10.1186/1756-8722-5-29.
  • 6Huang X J, Xu LP, Liu KY, et al. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia [J]. Biol Blood Marrow Transplant, 2011, 17 (5):649-656. doi: 10.1016/j.bbmt.2010. 07.023.
  • 7Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial[J]. Blood, 2012, 120( 14): 2826-2835. doi: 10.1182/blood-2012-06-435669.
  • 8Wang Y, Wu DP, Liu QF, et al. In adults with t (8;21)AML, post-transplant RUNX1/RIYNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification [J]. Blood, 2014, 124( 12):1880-1886. doi: 10.1182/blood-2014- 03-563403.
  • 9Tang X, Alatrash G, Ning J, et al. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time [ J ]. Biol Blood Marrow Transplant, 2014, 20 (8): 1139-1144. doi: 10.1016/j.bbmt.2014.04.003.
  • 10蒋瑛,万理萍,王椿,颜式可,高彦荣,姜杰玲,杨隽,蔡宇,白海涛,魏道林,谢匡成.异基因造血干细胞移植后细胞嵌合状态动态监测的临床意义[J].中华血液学杂志,2008,29(10):667-671. 被引量：9

二级参考文献31

  • 1李大启,王椿,秦尤文,张帆,谢匡成,颜式可,金力,赵寿元.异基因外周血干细胞移植后淋巴细胞和粒细胞嵌合体的动态改变[J].临床血液学杂志,2005,18(2):67-70. 被引量：8
  • 2万理萍,王椿,颜式可,李大启,秦尤文,谢匡成.异基因造血干细胞移植后的嵌合状态分析[J].中华内科杂志,2006,45(6):485-488. 被引量：10
  • 3Nollet F, Billict J, Selleslag D, et al. Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing. Bone Marrow Transplant ,2001,28:511-518.
  • 4Mattsson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablativc conditioning and allogeneic stem cell transplantation. Br J Haematol, 2001, 115: 935 -944.
  • 5McCann SR, Lawler M. Monitoring outcome: MRD; chimaerism and relapse. The EBMT hand book-haemopoietic stem cell transplantation 2004 Revised Edition. 197-212.
  • 6Mattsson J, Uzunel M, Remberger M, et al. Fraetionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation. Bone Marrow Transplant, 2003, 32:477-483.
  • 7Mohty M, Avinens O, Faucher C, et al. Predictive faclors and impaet of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica, 2007, 92 : 1004-1006.
  • 8Miura Y, Tanaka J, Toubai T, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-mveloablative stem cell transplantation. Bone Marrow Transplant, 2006,37:837-843.
  • 9Barrios M, Jimenez-Velaseo A, Roman-Gomez J, et al. Chimerism status is a useful predletor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica, 2003, 88:801- 810.
  • 10Marks DI, Lush R, Cavenagh J, et al. The toxicity and efficaev of donor lymphocyte infusions given after reduced-intensity conditioning allogeneie stem cell transplantation. Blood, 2002, 100: 3108- 3114.

共引文献21

同被引文献97

引证文献32

二级引证文献145

中华血液学杂志
2016年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部